Abstract library

792 results for "Overall Survival".
#300 Association Between Time to Disease Progression Endpoints and Overall Survival in Patients with Neuroendocrine Tumors
Introduction: While the association between time to disease progression (TDP) and overall survival (OS) has been examined in a variety of cancers, it has not been assessed in trials of neuroendocrine tumors (NETs).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Thomas E Delea
#336 Overall Survival (OS) Analysis of Sunitinib (SU) After Adjustment for Crossover (CO) in Patients With Pancreatic Neuroendocrine Tumors (NET)
Introduction: A recent phase 3 trial of SU in pancreatic NET showed an improvement in progression-free survival (PFS) and OS. However, the OS benefit was confounded by early CO from placebo (PBO) to SU treatment.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Jack Ishak
#445 Comparison of Prognostic Capacity for Overall Survival (OS) and Disease-Free Survival (DFS) of Neuroendocrine Tumors (NETs) Classifications: 2010 WHO, TNM Staging-ENETS and AJCC
Introduction: Current NETs classifications are: WHO, ENETS and AJCC. No consensus exists about which one more accurately predicts NET outcomes.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dra Nuria Mulet-Margalef
#158 Progression-free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs)
Introduction: Successfully testing new antitumor agents requires primary study endpoints that are clinically important, and also provide sufficient statistical power within a timeframe and population size that is feasible for the tumor type. Using overall survival (OS) as the primary endpoint in NET studies is challenging because of the low incidence (5.25/100,000 annually), disease heterogeneity, extended survival time (Yao 2008), and confounding effects of multiple therapies. These inherent aspects of NETs make OS an extremely difficult and challenging endpoint to evaluate clinical efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C, ...
#599 Rectal Neuroendocrine Tumors: Long-Term Survival After Resection and Prognostic Factors
Introduction: The rectum is the third most common location for gastrointestinal carcinoids after small bowel and colon. Due to their rarity, the characteristics and behavior of this unusual malignancy remain unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Cai Jianqiang
Authors: Du F, Chi Y H B L, Zhao H, Wang J W, ...
#36 A monocentric analysis of patients with pulmonary neuroendocrine tumors over 15 years: long term survival and life quality dependent from histological subtypes and surgical management
Introduction: Pulmonary neuroendocrine tumors substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized interdisciplinary centers, a broad therapeutical armentarium can be used to achieve optimal treatment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Johannes N Hoffmann
Authors: Zahn S, Hornung H, Schick K S, Winter H, ...
#250 Circulating Tumor Cells (CTCs) Correlate with Overall Survival in Neuroendocrine Tumors (NETs)
Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated. We have previously shown that CTCs are detectable in NETs and associated with progressive disease.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#470 Overall Survival of Well-Differentiated Neuroendocrine Tumors Evaluated by F-18-FDG-PET
Introduction: Today, grading, and thereby choice of treatment strategy for patients with neuroendocrine (NE) tumors, is mainly based on the proliferation index, Ki-67. As a supplement to this pathological evaluation, a whole body image analysis could be of value.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MSc, PhD Tina Binderup
#1313 C-Reactive Protein As a New Prognostic Factor for Overall Survival in Patients with Pancreatic Neuroendocrine Neoplasia
Introduction: For many cancer entities, inflammation has been shown to play an important role in pathogenesis and progression.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Prof. Dr. Volker Fendrich
Keywords: CRP, prognosis, pNEN, survival
#1450 Chilean Neuroendocrine Tumours Hospital Registry: Initial Data of a Latin-America Perspective.
Introduction: Neuroendocrine tumours (NET) have increasing area of clinical and scientific research. The NET registry of the Pontificia Universidad Católica de Chile (PUC) is the first chilean database which systematically collects data on patients with neuroendocrine tumours.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Marcelo Garrido
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.